231 related articles for article (PubMed ID: 23272171)
21. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
22. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
23. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
25. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
26. MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway.
Sun DM; Tang BF; Li ZX; Guo HB; Cheng JL; Song PP; Zhao X
Sci Rep; 2018 May; 8(1):8007. PubMed ID: 29789623
[TBL] [Abstract][Full Text] [Related]
27. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
28. A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells.
Li H; Zhang W; Zhao K; Zhao D; Zheng S; Hu Y
J Biol Chem; 2020 Mar; 295(12):4049-4063. PubMed ID: 32005663
[TBL] [Abstract][Full Text] [Related]
29. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
30. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
31. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J
Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289
[TBL] [Abstract][Full Text] [Related]
32. Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen.
Wang LJ; Li J; Hao FR; Yuan Y; Li JY; Lu W; Zhou TY
Acta Pharmacol Sin; 2016 Jun; 37(6):845-56. PubMed ID: 27133297
[TBL] [Abstract][Full Text] [Related]
33. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
[TBL] [Abstract][Full Text] [Related]
34. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
Sun X; Shi B; Zheng H; Min L; Yang J; Li X; Liao X; Huang W; Zhang M; Xu S; Zhu Z; Cui H; Liu X
Cell Death Dis; 2018 Feb; 9(3):260. PubMed ID: 29449532
[TBL] [Abstract][Full Text] [Related]
35. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
38. Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; Richard DJ; O'Byrne KJ; Adams MN; Baird AM
Lung Cancer; 2019 Sep; 135():217-227. PubMed ID: 31446998
[TBL] [Abstract][Full Text] [Related]
39. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
[TBL] [Abstract][Full Text] [Related]
40. Dexamethasone induces cancer mitigation and irreversible senescence in lung cancer cells via damaging cortical actin and sustained hyperphosphorylation of pRb.
Srivastava S; Siddiqui S; Singh S; Chowdhury S; Upadhyay V; Sethi A; Kumar Trivedi A
Steroids; 2023 Oct; 198():109269. PubMed ID: 37394085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
